BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu C, Shen Y, Cheng C, Hu F, Cheng A. Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials 2010;31:55-61. [DOI: 10.1016/j.cct.2009.08.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Hsu C, Shen YC, Cheng CC, Cheng AL, Hu FC, Yeh KH. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression. Gastric Cancer. 2012;15:265-280. [PMID: 22576708 DOI: 10.1007/s10120-012-0151-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
2 Hsu C, Shen Y, Cheng C, Cheng A, Hu F, Yeh K. Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer 2012;15:265-80. [DOI: 10.1007/s10120-011-0106-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
3 Chan FK, Cheng KC. Laparoscopic liver resection: western versus eastern experience. Chin J Cancer Res 2014;26:243-4. [PMID: 25035649 DOI: 10.3978/j.issn.1000-9604.2014.06.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ma WL, Jeng LB, Lai HC, Liao PY, Chang C. Androgen receptor enhances cell adhesion and decreases cell migration via modulating β1-integrin-AKT signaling in hepatocellular carcinoma cells. Cancer Lett 2014;351:64-71. [PMID: 24944078 DOI: 10.1016/j.canlet.2014.05.017] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
5 Shen YC, Hsu C, Cheng CC, Hu FC, Cheng AL. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology. 2012;82:275-289. [PMID: 22555181 DOI: 10.1159/000337293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
6 Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, Huang J. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends 2022. [PMID: 35173139 DOI: 10.5582/bst.2022.01044] [Reference Citation Analysis]
7 Xing YX, Li MH, Tao L, Ruan LY, Hong W, Chen C, Zhao WL, Xu H, Chen JF, Wang JS. Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by 1H NMR Based Metabolic Profiling. J Proteome Res 2018;17:1943-52. [PMID: 29676152 DOI: 10.1021/acs.jproteome.8b00029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
8 Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116:4590-4596. [PMID: 20572033 DOI: 10.1002/cncr.25257] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 9.2] [Reference Citation Analysis]
9 Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010;53:126-131. [PMID: 20416968 DOI: 10.1016/j.jhep.2010.01.035] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
10 Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/Leucovorin vs doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501-3508. [PMID: 23980077 DOI: 10.1200/jco.2012.44.5643] [Cited by in Crossref: 218] [Cited by in F6Publishing: 138] [Article Influence: 24.2] [Reference Citation Analysis]
11 Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol 2014; 20(30): 10249-10261 [PMID: 25132742 DOI: 10.3748/wjg.v20.i30.10249] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
12 Chang Y, Tai C, Kuo L, Wei P, Liang H, Liu T, Wang W, Tai C, Ho Y, Wu C, Huang M. Glucose-Regulated Protein 78 (GRP78) Mediated the Efficacy to Curcumin Treatment on Hepatocellular Carcinoma. Ann Surg Oncol 2011;18:2395-403. [DOI: 10.1245/s10434-011-1597-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
13 Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57:1013-1020. [PMID: 22732513 DOI: 10.1016/j.jhep.2012.06.022] [Cited by in Crossref: 113] [Cited by in F6Publishing: 123] [Article Influence: 11.3] [Reference Citation Analysis]
14 Li L, Yeo W. Value of quality of life analysis in liver cancer: A clinician’s perspective. World J Hepatol 2017; 9(20): 867-883 [PMID: 28804570 DOI: 10.4254/wjh.v9.i20.867] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
15 Liu Y, Yue H, Xu S, Wang F, Ma N, Li K, Qiao L, Wang J. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol. 2015;20:952-959. [PMID: 25712158 DOI: 10.1007/s10147-015-0796-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
16 Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S74-9. [PMID: 25755615 DOI: 10.1016/j.jceh.2014.03.045] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
17 Chan SL, Johnson PJ, Mo F, Berhane S, Teng M, Chan AW, Poon MC, Lai PB, Yu S, Chan AT. International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer. 2014;33:481-491. [PMID: 25223914 DOI: 10.5732/cjc.014.10133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
18 Yeo W, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Yeoh EM, Ye SL. Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010;10:620. [PMID: 21062497 DOI: 10.1186/1471-2407-10-620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
19 Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials 2014;15:474. [PMID: 25472660 DOI: 10.1186/1745-6215-15-474] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
20 Shen Y, Hsu C, Cheng A. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807. [DOI: 10.1007/s00535-010-0270-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
21 Whang-peng J, Cheng A, Hsu C, Chen C. Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental & Clinical Medicine 2010;2:93-103. [DOI: 10.1016/s1878-3317(10)60016-2] [Cited by in Crossref: 18] [Article Influence: 1.5] [Reference Citation Analysis]
22 Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, Kumada T. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441-447. [PMID: 28081537 DOI: 10.1038/bjc.2016.422] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
23 Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2021;6:559-68. [PMID: 33971141 DOI: 10.1016/S2468-1253(21)00109-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
24 Pinato DJ, Arizumi T, Jang JW, Allara E, Suppiah PI, Smirne C, Tait P, Pai M, Grossi G, Kim YW, Pirisi M, Kudo M, Sharma R. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. Oncotarget 2016;7:44705-18. [PMID: 27244889 DOI: 10.18632/oncotarget.9604] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
25 Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Stebbing J, Kudo M, Jang JW, Sharma R. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2014;40:1270-81. [DOI: 10.1111/apt.12992] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
26 Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102:981-986. [PMID: 20160718 DOI: 10.1038/sj.bjc.6605580] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 7.3] [Reference Citation Analysis]
27 Yau T, Pang R, Chan P, Poon RT. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opinion on Pharmacotherapy 2010;11:2187-98. [DOI: 10.1517/14656561003724705] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
28 Lai HC, Yeh CC, Jeng LB, Huang SF, Liao PY, Lei FJ, Cheng WC, Hsu CL, Cai X, Chang C, Ma WL. Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. Oncotarget 2016;7:46448-65. [PMID: 27340775 DOI: 10.18632/oncotarget.10186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
29 Hsu C, Shen Y, Yu C, Hsu C, Hu F, Hsu C, Chen B, Wei S, Cheng A, Shih TT. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Journal of Hepatology 2011;55:858-65. [DOI: 10.1016/j.jhep.2011.01.032] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 7.9] [Reference Citation Analysis]
30 Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 2016;16:856. [PMID: 27821083 DOI: 10.1186/s12885-016-2868-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
31 Li L, Mo F, Hui EP, Chan SL, Koh J, Tang NLS, Yu SCH, Yeo W. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol 2019;19:66. [PMID: 31046687 DOI: 10.1186/s12876-019-0984-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
32 Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V. VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Res Protoc 2017;6:e17. [PMID: 28202430 DOI: 10.2196/resprot.7016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
33 Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102:981-986. [PMID: 20160718 DOI: 10.1038/sj.bjc.660558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Chang Y, Li L, Chen H, Hung C, Wei P. Silencing survivin activates autophagy as an alternative survival pathway in HCC cells. Tumor Biol 2014;35:9957-66. [DOI: 10.1007/s13277-014-2257-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
35 Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S, Bonnetain F. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013;58:81-88. [PMID: 22989572 DOI: 10.1016/j.jhep.2012.09.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
36 Wang P, Tian M, Ren W. Correlation Between Contrast-Enhanced Ultrasound and Immune Response of Distant Hepatocellular Carcinoma After Radiofrequency Ablation in a Murine Model. J Ultrasound Med 2021. [PMID: 34018628 DOI: 10.1002/jum.15753] [Reference Citation Analysis]